12/14
01:26 am
rntx
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at
Wall Stree
Medium
Report
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at
Wall Stree
11/6
07:30 am
rntx
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Low
Report
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
11/3
06:10 pm
rntx
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
High
Report
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
11/3
05:03 pm
rntx
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
High
Report
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
11/3
07:30 am
rntx
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
10/9
08:01 am
rntx
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Low
Report
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
10/9
07:30 am
rntx
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis